{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:36:46Z","timestamp":1778701006928,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:00:00Z","timestamp":1587859200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Education, Culture and Sport"},{"DOI":"10.13039\/501100004587","name":"\u2018Instituto de Salud Carlos III\u2019","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"\u2018Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca\u2019","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Initiation of combination antiretroviral therapy (cART) soon after HIV-1 infection limits the establishment of viral reservoirs. Thus, early treated individuals are preferred candidates to evaluate novel viral remission strategies. However, their cART-dependent HIV-1 DNA decay dynamics are still poorly defined. This can hamper the design and interpretation of results from clinical trials intended to further reduce viral reservoirs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To clarify the duration of cART needed for the HIV-1 reservoir to be stabilized in early treated individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We characterized the longitudinal decline of total HIV-1 DNA levels by droplet digital PCR in 21 individuals initiating cART within 6\u2009months after estimated HIV-1 acquisition. Measurements were taken at cART initiation, after 6\u2009months and annually until Year 4. Correlations between virological and clinical parameters were statistically analysed. Statistical modelling was performed applying a mixed-effects model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Total HIV-1 DNA experienced a median overall decrease of 1.43\u2009log10\u2009units (IQR\u2009=\u20091.17\u20131.69) throughout the 4\u2009years of follow-up. Baseline levels for total HIV-1 DNA, viral load, absolute CD4+ T cell count and CD4+\/CD8+ ratio correlate with final HIV-1 DNA measurements (R2\u2009=\u20090.68, P\u2009&amp;lt;\u20090.001; R2\u2009=\u20090.54, P\u2009=\u20090.012; R2\u2009=\u2009\u22120.47, P\u2009=\u20090.031; and R2\u2009=\u2009\u22120.59, P\u2009=\u20090.0046, respectively). Statistical modelling shows that after 2\u2009years on cART the viral reservoir had reached a set point.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A waiting period of 2\u2009years on cART should be considered when designing interventions aiming to impact latent HIV-1 reservoir levels and viral rebound kinetics after cART discontinuation, in order to facilitate interpretation of results and enhance the chance of viral control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa139","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T20:09:54Z","timestamp":1584734994000},"source":"Crossref","is-referenced-by-count":3,"title":["HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design"],"prefix":"10.1093","author":[{"given":"\u00c1ngel","family":"Bay\u00f3n-Gil","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C","family":"Puertas","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Urrea","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"first","affiliation":[{"name":"Fight AIDS Foundation (FLS), Infectious Disease Service, Germans Trias i Pujol University Hospital, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mor\u00f3n-L\u00f3pez","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Cobars\u00ed","sequence":"first","affiliation":[{"name":"Fight AIDS Foundation (FLS), Infectious Disease Service, Germans Trias i Pujol University Hospital, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Brander","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"University of Vic\u2014Central University of Catalonia (UVic-UCC), Vic, Spain"},{"name":"Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain"},{"name":"Aelix Therapeutics, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Mothe","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"Fight AIDS Foundation (FLS), Infectious Disease Service, Germans Trias i Pujol University Hospital, Badalona, Spain"},{"name":"University of Vic\u2014Central University of Catalonia (UVic-UCC), Vic, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"first","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Badalona, Spain"},{"name":"University of Vic\u2014Central University of Catalonia (UVic-UCC), Vic, Spain"},{"name":"Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"2020042605454701500_dkaa139-B1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dks533","article-title":"Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts","volume":"68","author":"Hocqueloux","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020042605454701500_dkaa139-B2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/infdis\/jit311","article-title":"Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size","volume":"208","author":"Jain","year":"2013","journal-title":"J Infect Dis"},{"key":"2020042605454701500_dkaa139-B3","doi-asserted-by":"crossref","first-page":"e33948","DOI":"10.1371\/journal.pone.0033948","article-title":"Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection","volume":"7","author":"Ananworanich","year":"2012","journal-title":"PLoS One"},{"key":"2020042605454701500_dkaa139-B4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2016.07.024","article-title":"HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART","volume":"11","author":"Ananworanich","year":"2016","journal-title":"EBioMedicine"},{"key":"2020042605454701500_dkaa139-B5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciu585","article-title":"HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy","volume":"59","author":"Besson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020042605454701500_dkaa139-B6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0000000000001948","article-title":"HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients","volume":"32","author":"Golob","year":"2018","journal-title":"AIDS"},{"key":"2020042605454701500_dkaa139-B7","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1038\/ncomms9495","article-title":"Immunological biomarkers predict HIV-1 viral rebound after treatment interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat Commun"},{"key":"2020042605454701500_dkaa139-B8","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"2020042605454701500_dkaa139-B9","doi-asserted-by":"crossref","first-page":"e03821","DOI":"10.7554\/eLife.03821","article-title":"HIV-1 DNA predicts disease progression and post-treatment virological control","volume":"3","author":"Williams","year":"2014","journal-title":"Elife"},{"key":"2020042605454701500_dkaa139-B10","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32834b9658","article-title":"Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir","volume":"25","author":"Koelsch","year":"2011","journal-title":"AIDS"},{"key":"2020042605454701500_dkaa139-B11","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1128\/JVI.01046-14","article-title":"Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells","volume":"88","author":"Buzon","year":"2014","journal-title":"J Virol"},{"key":"2020042605454701500_dkaa139-B12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection","volume":"17","author":"Fiebig","year":"2003","journal-title":"AIDS"},{"key":"2020042605454701500_dkaa139-B13","doi-asserted-by":"crossref","first-page":"e0175899","DOI":"10.1371\/journal.pone.0175899","article-title":"Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue","volume":"12","author":"Mor\u00f3n-L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"2020042605454701500_dkaa139-B14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.0006-341X.1999.00410.x","article-title":"Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials","volume":"55","author":"Wu","year":"1999","journal-title":"Biometrics"},{"key":"2020042605454701500_dkaa139-B15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2796.2011.02457.x","article-title":"HIV reservoirs and the possibility of a cure for HIV infection","volume":"270","author":"Palmer","year":"2011","journal-title":"J Intern Med"},{"key":"2020042605454701500_dkaa139-B16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/civ171","article-title":"Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA","volume":"60","author":"Laanani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020042605454701500_dkaa139-B17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QAI.0000000000000111","article-title":"A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals","volume":"66","author":"Markowitz","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020042605454701500_dkaa139-B18","doi-asserted-by":"crossref","first-page":"ofv138","DOI":"10.1093\/ofid\/ofv138","article-title":"Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency virus (HIV) infection does not accelerate HIV reservoir reduction","volume":"2","author":"Ostrowski","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2020042605454701500_dkaa139-B19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tim.2015.01.013","article-title":"Towards an HIV-1 cure: measuring the latent reservoir","volume":"23","author":"Bruner","year":"2015","journal-title":"Trends Microbiol"},{"key":"2020042605454701500_dkaa139-B20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12977-018-0392-7","article-title":"Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs","volume":"15","author":"Baxter","year":"2018","journal-title":"Retrovirology"},{"key":"2020042605454701500_dkaa139-B21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med"},{"key":"2020042605454701500_dkaa139-B22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa139\/33129399\/dkaa139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa139\/33129399\/dkaa139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T09:46:04Z","timestamp":1587894364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkaa139\/5825343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa139","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"article-number":"dkaa139"}}